Galaxy Diagnostics is structured around increasing awareness of the emerging research of bartonellosis among key stakeholders in medicine, public health and the veterinary community and to offer the best possible clinical testing for confirmation of Bartonella species bacteremia. As a social venture and a One Health company, Galaxy Diagnostics is comitted to protecting the animal-human bond through the surveillance, prevention and clinical management of diseases shared by humans and animals. Offering the best molecular and serology test options available, the firm also works with researchers and clinicians to generate new knowledge about emerging infectious diseases such as bartonellosis, borreliosis and other vector-borne diseases, providing counsel to clinicians and researchers to enable the most accurate diagnosis possible for their patients. This central goal is reflected in our corporate values and everyday interaction with patients, clinicians and researchers. Galaxy Diagnostics was orignally founded to commercialize a more sensitive test for Bartonella species infection (e.g., bartonellosis, cat scratch disease, trench fever, etc.), based on a proprietary technology called Bartonella Alpha Proteobacteria Growth Medium (BAPGM), developed by scientists at North Carolina State Universityâs College of Veterinary Medicine. The One Health approach recognizes that the health of people is connected to the health of animals and the environment: For every TEN infectious diseases in humans, SIX are spread from animals. The goal of One Health is to encourage collaborative efforts across multiple disciplines working locally, nationally and globally to achieve the best health for people, animals and the environment.
